Foley Hoag Congratulates Predictive Biosciences on Series C Financing
June 16, 2010
Foley Hoag LLP congratulates its client Predictive Biosciences, Inc. on the closing of a $25 million Series C preferred stock financing. Predictive, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, will use the proceeds of the financing to complete multi-center clinical trials for Predictive’s CertNDx bladder cancer assay and support its commercial launch.
Lawyers in FoleyHoag’s Life Sciences group have represented Predictive Biosciences since December 2006. The transaction team consisted of Jeffrey Quillen, partner and co-chair of the firm’s Life Sciences practice, and associates Joel Needleman, Michelle Limaj and Patrick Connolly.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.